Vijay Ramanath, MD
Interventional Cardiology · Plano, TXNPI 1003841297
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (33.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Boston Scientific at 32.3% of the total. Reporting peaked in 2019 at $36,833 and has fallen 72.3% since, to $10,190 in 2025. Among interventional cardiology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,032 payments — averaging $91.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$30K
- Medtronic$17K
- Terumo Medical Corporation$8K
- Penumbra, Inc.$6K
- Angiodynamics, Inc.$6K
- Edwards Lifesciences$4K
- plus $24K from 54 others
Across 147 payments — averaging $2340.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$162K
- Novartis$138K
- Abbott$42K
- W. L. Gore & Associates, Inc.$3K
What the payments were for
- Consulting fees$25,77527%
- Speaking & faculty fees$8,0008%
- Grants$1,1231%
- Travel & lodging$23,02124%
- Food & beverage$31,17233%
- Education$1200%
- Entertainment$440%
- Other$5,1255%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$12,768
- Resolute$8,313
- TR Band$5,176
- Auryon Laser System 100-120 Vac$5,125
- GENERAL VASCULAR INTERVENTION$4,013
- ANGIOJET$3,500
- Indigo System$2,999
- Vascular Lithotripsy$2,914
- ELUVIA$2,705
- Peripheral Orbital Atherectomy System$2,422
- COREVALVE EVOLUT R$2,361
- Indigo$2,225
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,113
- CoreValve Evolut$1,733
- Glidesheath$1,225
- 3F$1,123
- EXCLUDER AAA Endoprosthesis$995
- Optitorque$700
- Heartrail$700
- Micra$631
How this compares
$94,380 in reported general payments places this provider in the 90th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 429 | $514,297 |
| XareltoRivaroxaban | 120 | $163,269 |
| Repatha SureclickEvolocumab | 56 | $63,360 |
| EntrestoSacubitril/Valsartan | 42 | $60,381 |
| BrilintaTicagrelor | 62 | $52,023 |
| Praluent PenAlirocumab | 14 | $13,399 |
| VascepaIcosapent Ethyl | 16 | $11,593 |
| Atorvastatin Calcium | 429 | $4,299 |
| Metoprolol Succinate | 263 | $3,521 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 15 | $3,409 |
| ClopidogrelClopidogrel Bisulfate | 170 | $2,551 |
| Losartan Potassium | 223 | $2,223 |
| Carvedilol | 294 | $2,066 |
| Amlodipine Besylate | 239 | $1,854 |
| Lisinopril | 187 | $1,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $883 | $514,297429 claims |
| Johnson & JohnsonXarelto | $1,438 | $163,269120 claims |
| NovartisEntresto | $1,148 | $60,38142 claims |
| AstraZenecaBrilinta | $475 | $52,02362 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Plano
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Molly SzerlipPlano$130K
- Chadi DibPlano$84K
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.